Literature DB >> 33507222

Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement.

Rachel A Freedman1, Christina A Minami2, Eric P Winer1, Monica Morrow3, Alexander K Smith4,5, Louise C Walter4,5, Mina S Sedrak6, Haley Gagnon1, Adriana Perilla-Glen1, Hans Wildiers7, Tanya M Wildes8, Stuart M Lichtman9, Kah Poh Loh10, Etienne G C Brain11, Pamela S Ganschow12, Kelly K Hunt13, Deborah K Mayer14,15, Kathryn J Ruddy16, Reshma Jagsi17,18, Nancy U Lin1, Beverly Canin19, Barbara K LeStage20,21, Anna C Revette22, Mara A Schonberg23, Nancy L Keating24,25.   

Abstract

IMPORTANCE: There is currently no guidance on how to approach surveillance mammography for older breast cancer survivors, particularly when life expectancy is limited.
OBJECTIVE: To develop expert consensus guidelines that facilitate tailored decision-making for routine surveillance mammography for breast cancer survivors 75 years or older. EVIDENCE: After a literature review of the risk of ipsilateral and contralateral breast cancer events among breast cancer survivors and the harms and benefits associated with mammography, a multidisciplinary expert panel was convened to develop consensus guidelines on surveillance mammography for breast cancer survivors 75 years or older. Using an iterative consensus-based approach, input from clinician focus groups, and critical review by the International Society for Geriatric Oncology, the guidelines were refined and finalized.
FINDINGS: The literature review established a low risk for ipsilateral and contralateral breast cancer events in most older breast cancer survivors and summarized the benefits and harms associated with mammography. Draft mammography guidelines were iteratively evaluated by the expert panel and clinician focus groups, emphasizing a patient's risk for in-breast cancer events, age, life expectancy, and personal preferences. The final consensus guidelines recommend discontinuation of routine mammography for all breast cancer survivors when life expectancy is less than 5 years, including those with a history of high-risk cancers; consideration to discontinue mammography when life expectancy is 5 to 10 years; and continuation of mammography when life expectancy is more than 10 years. Individualized, shared decision-making is encouraged to optimally tailor recommendations after weighing the benefits and harms associated with surveillance mammography and patient preferences. The panel also recommends ongoing clinical breast examinations and diagnostic mammography to evaluate clinical findings and symptoms, with reassurance for patients that these practices will continue. CONCLUSIONS AND RELEVANCE: It is anticipated that these expert guidelines will enhance clinical practice by providing a framework for individualized discussions, facilitating shared decision-making regarding surveillance mammography for breast cancer survivors 75 years or older.

Entities:  

Mesh:

Year:  2021        PMID: 33507222      PMCID: PMC8944384          DOI: 10.1001/jamaoncol.2020.7582

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   33.006


  43 in total

1.  Talking about stopping cancer screening-not so easy.

Authors:  Mara A Schonberg; Louise C Walter
Journal:  JAMA Intern Med       Date:  2013-04-08       Impact factor: 21.873

Review 2.  Epidemiology of contralateral breast cancer.

Authors:  Y Chen; W Thompson; R Semenciw; Y Mao
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-10       Impact factor: 4.254

3.  Cancer treatment and survivorship statistics, 2019.

Authors:  Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2019-06-11       Impact factor: 508.702

4.  United States Life Tables, 2017.

Authors:  Elizabeth Arias
Journal:  Natl Vital Stat Rep       Date:  2019-06

5.  Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy.

Authors:  Rachel A Freedman; Nancy L Keating; Lydia E Pace; Joyce Lii; Ellen P McCarthy; Mara A Schonberg
Journal:  J Clin Oncol       Date:  2017-07-27       Impact factor: 44.544

6.  Causes of death and relative survival of older women after a breast cancer diagnosis.

Authors:  Mara A Schonberg; Edward R Marcantonio; Long Ngo; Donglin Li; Rebecca A Silliman; Ellen P McCarthy
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

7.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

8.  Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Authors:  Kevin S Hughes; Lauren A Schnaper; Donald Berry; Constance Cirrincione; Beryl McCormick; Brenda Shank; Judith Wheeler; Lorraine A Champion; Thomas J Smith; Barbara L Smith; Charles Shapiro; Hyman B Muss; Eric Winer; Clifford Hudis; William Wood; David Sugarbaker; I Craig Henderson; Larry Norton
Journal:  N Engl J Med       Date:  2004-09-02       Impact factor: 91.245

9.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.

Authors:  Paul L Nguyen; Alphonse G Taghian; Matthew S Katz; Andrzej Niemierko; Rita F Abi Raad; Whitney L Boon; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris
Journal:  J Clin Oncol       Date:  2008-04-14       Impact factor: 44.544

10.  Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies.

Authors:  Hyunsoon Cho; Carrie N Klabunde; K Robin Yabroff; Zhuoqiao Wang; Angela Meekins; Iris Lansdorp-Vogelaar; Angela B Mariotto
Journal:  Ann Intern Med       Date:  2013-11-19       Impact factor: 25.391

View more
  2 in total

1.  Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.

Authors:  Erin J Aiello Bowles; Cody Ramin; Diana S M Buist; Heather Spencer Feigelson; Sheila Weinmann; Lene H S Veiga; Clara Bodelon; Rochelle E Curtis; Jacqueline B Vo; Amy Berrington de Gonzalez; Gretchen L Gierach
Journal:  Breast Cancer Res Treat       Date:  2022-03-11       Impact factor: 4.872

2.  Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors.

Authors:  Rachel A Freedman; Anna C Revette; Haley Gagnon; Adriana Perilla-Glen; Molly Kokoski; Saida O Hussein; Erin Leone; Nicole Hixon; Rebeka Lovato; Wendy Loeser; Nancy U Lin; Christina A Minami; Beverly Canin; Barbara LeStage; Meredith Faggen; Philip D Poorvu; Jennifer McKenna; Kathryn J Ruddy; Nancy L Keating; Mara A Schonberg
Journal:  Breast Cancer Res Treat       Date:  2022-07-30       Impact factor: 4.624

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.